Form 4: Jazz Pharma CEO's Share Transaction
Insider Transaction Report
Jazz Pharmaceuticals' President & CEO, Renee D Gala, reported a disposition of 80 ordinary shares for tax purposes and an acquisition of 71 shares via an employee stock plan.
Summary
- Renee D Gala, President & CEO of Jazz Pharmaceuticals plc, reported a transaction involving ordinary shares.
- On December 5, 2025, 80 ordinary shares were disposed of at a price of $166.91 per share.
- The disposition was marked with transaction code 'F', typically indicating a transaction to cover tax liability.
- Following this transaction, Renee D Gala beneficially owns 107,860 ordinary shares.
- An additional 71 ordinary shares were acquired by the Reporting Person under a Section 423 Employee Stock Purchase Plan on November 28, 2025.
Sentiment
Score: 5
Explanation: The filing reports routine insider transactions, including a tax-related disposition and a small acquisition via an employee stock plan. These events are generally neutral in sentiment and do not indicate significant positive or negative developments for the company.
Positives
- The acquisition of 71 ordinary shares through an Employee Stock Purchase Plan indicates continued participation and investment by the CEO in the company's equity.
Negatives
- The disposition of 80 ordinary shares was for tax purposes, which is a routine event and not indicative of a negative outlook on the company.
Future Outlook
NA
Industry Context
This filing is a standard insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's share activity.
Stakeholder Impact
- Shareholders: Minimal impact as this is a routine, small-scale insider transaction for tax purposes and an employee stock plan acquisition, not indicating a change in management's confidence or strategic direction.
Key Dates
| Date | Description |
|---|---|
| 11/28/2025 | Reporting Person acquired 71 ordinary shares under a Section 423 Employee Stock Purchase Plan. |
| 12/05/2025 | Transaction date for the disposition of 80 ordinary shares. |
| 12/09/2025 | Signature date of the reporting person's attorney-in-fact. |
Keywords
Jazz Pharmaceuticals, JAZZ, Insider Trading, Form 4, Share Disposition, Employee Stock Purchase Plan, CEO, Renee D Gala, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.